Hepatitis C News and Research

Latest Hepatitis C News and Research

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

6 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Medivir strengthens hepatitis C platform

Medivir AB, announced today that it has acquired preclinical research stage assets from Novadex Pharmaceuticals AB. The acquisition includes intellectual property and prodrug technologies in order to further strengthen Medivir's hepatitis C platform and know how.

5 Sep 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

FDA approves Gilead’s Stribild to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

28 Aug 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Novira Therapeutics Inc. today announced it has secured $23 million in Series A financing to support the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.

24 Aug 2012

Bristol-Myers Squibb terminates BMS-986094 Phase II development for treatment of hepatitis C

Bristol-Myers Squibb Company announced today that the Company has discontinued development of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor that was in Phase II development for the treatment of hepatitis C.

24 Aug 2012

New book sparks debate over whether vaccines cause autism

The bitter debate over whether vaccines cause autism is masking real problems with the modern inoculation schedule and encouraging a growing number of parents to refuse recommended vaccines for their children, argues a Michigan State University scholar.

23 Aug 2012

Article describes immune-related adverse events with newly approved melanoma drug

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.

23 Aug 2012

One blog examines GAVI Alliance's efforts to accelerate introduction of hepatitis B vaccines in developing countries

"I am looking forward to participating in the 2012 World Cancer Leaders' Summit, to be held in Montreal, Canada on August 27," GAVI Alliance Deputy CEO Helen Evans writes in this post in the One Blog.

23 Aug 2012

Study identifies how RNA viruses hijack a host cell to multiply

By discovering how certain viruses use their host cells to replicate, UC Irvine microbiologists have identified a new approach to the development of universal treatments for viral illnesses such as meningitis, encephalitis, hepatitis and possibly the common cold.

23 Aug 2012

Viewpoints: The importance of hepatitis C testing; Medicaid needs to provide coverage for circumcision

I consider myself to be a fortunate person. I have a good education, a great job and excellent health insurance. I am a baby boomer who has aged reasonably well and can look forward to a fairly comfortable retirement. I am also fortunate because I was diagnosed with hepatitis C by a proactive and knowledgeable doctor in the late 1990s and had the opportunity to be treated and cured. The odds are that if I had not been diagnosed and treated, I would be on a liver transplant list right now, have liver cancer or even be dead from this disease.

22 Aug 2012

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical phase Ib trial of the company's candidate drug (CD) MIV-711 has commenced.

21 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

Infectious disease rates are high among homeless people

Rates of the infectious diseases HIV, Hepatitis C and tuberculosis among the world’s homeless people are many times higher than in the general population, according to a new systematic review of existing data published Online First in The Lancet Infectious Diseases.

20 Aug 2012

CDC: Baby boomers should be tested for Hep C

Americans born between 1945 and 1965 are at particularly high risk for Hepatitis C and should be tested, according to new recommendations from the Centers for Disease Control and Prevention.

18 Aug 2012

Ohio's three Clinical and Translational Science Award institutions establish IRB agreement

The three Clinical and Translational Science Award (CTSA) institutions in Ohio — Case Western Reserve University, University of Cincinnati and The Ohio State University — and their partnering institutions have established a statewide collaborative agreement allowing a single organization's Institutional Review Board (IRB) to assume IRB responsibilities on behalf of multiple institutions when conducting multicenter studies.

18 Aug 2012

Hepatitis C News and Research

Latest Hepatitis C News and Research

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

Strong antiviral antibody response observed in oral administration of Flucide

Medivir strengthens hepatitis C platform

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

FDA approves Gilead’s Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Bristol-Myers Squibb terminates BMS-986094 Phase II development for treatment of hepatitis C

New book sparks debate over whether vaccines cause autism

Article describes immune-related adverse events with newly approved melanoma drug

One blog examines GAVI Alliance's efforts to accelerate introduction of hepatitis B vaccines in developing countries

Study identifies how RNA viruses hijack a host cell to multiply

Viewpoints: The importance of hepatitis C testing; Medicaid needs to provide coverage for circumcision

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Infectious disease rates are high among homeless people

CDC: Baby boomers should be tested for Hep C

Ohio's three Clinical and Translational Science Award institutions establish IRB agreement

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in